Aficamten - CAS# 2364554-48-1 Catalog No.:M33502-2 and significantly reduces expression of

and significantly reduces expression of VCAM-1

Analysis of the inhibition kinetics by double-reciprocal plot demonstrates that galangin inhibits CYP1A1 activity in a noncompetitive manner

Smiles: CN([C@H]1CN(CC[C@H]1C)C(=O)CC#N)C1N=CN=C2NC=CC2=1

InChiKey: BTUJMQIKTCOSFK-XKNHYIDFSA-N

injury and HCC also occur if hepatic S-Adenosyl-L-methionine level is excessive chronically

Aficamten - CAS# 2364554-48-1 Catalog No.:M33502-2 and significantly reduces expression ofAficamten, CAS No. 2364554 48 1, also known as CK 3773274 and CK 274, is a Next Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. Aficamten was designed to provide a predicted human half life (t1 2) appropriate for once a day (qd) dosing, to reach steady state within two weeks, to have no substantial cytochrome P450 induction or inhibition, and to have a wide therapeutic window in vivo with a clear pharmacokinetic